Background
==========

*PAX5* rearrangements, resulting in the expression of in-frame fusion genes, account for about 2.5% of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) \[[@B1]\]. While several groups, including our own, have reported the incidence and diversity of *PAX5* fusion genes \[[@B1]-[@B7]\], their occurrence in leukemia harboring a t(7;9)(q11.2;p13) or der(9)t(7;9)(q11.2;p13) has not yet been investigated in detail. Herein, we describe an additional case with a *PAX5-ELN* fusion and summarize the demographic and genetic data of all cases with t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) leukemia reported to date.

Case presentation
=================

We have identified an additional case of pediatric BCP-ALL with an infrequent der(9)t(7;9)(q11.23;p13) resulting in the expression of an in-frame *PAX5-ELN* fusion gene (Table [1](#T1){ref-type="table"}). Cytogenetic analysis of the bone marrow of a 19.4-year-old adolescent revealed - together with many secondary aberrations - a der(9)t(7;9)(q11.2;p13) (Figure [1](#F1){ref-type="fig"}A) and subsequent FISH analysis using *PAX5*-flanking BAC clones showed a deletion of the 3′-end-specific probe, which is suggestive of a *PAX5* gene rearrangement (Figure [1](#F1){ref-type="fig"}B). Further FISH analysis, using *PAX5*- and *ELN*-specific clones, identified *ELN* as the fusion partner (Figure [1](#F1){ref-type="fig"}C), which was verified on the molecular level by RT-PCR (Figure [1](#F1){ref-type="fig"}D). Sequencing of the amplification product showed that exon 7 of *PAX5* was fused to exon 5 of *ELN* (Figure [1](#F1){ref-type="fig"}E). In all *PAX5-ELN* cases, except for one in which *PAX5* exon 5 was fused to *ELN* sequences, the breakpoints in *PAX5* occurred in intron 7 \[[@B2],[@B4],[@B8]\]. Also, the breakpoints in *ELN* are heterogeneous and *PAX5* is fused to either exon 2 or exon 5 of *ELN* (Table [1](#T1){ref-type="table"}) \[[@B2],[@B4],[@B8]\]. Consequently, the consensus PAX5-ELN fusion protein consists of the DNA-binding paired domain, the octapeptide, and the nuclear localization signal of PAX5, which are fused to almost the entire ELN protein without the signal peptide (Figure [2](#F2){ref-type="fig"}).

###### 

Demographic and genetic data of t(7;9)(q11.2;p13) and der(9)t(7;9)(q11.2;p13) positive B-ALL cases

                             **Case**                              **Age**   **Sex**   **Phenotype**  **Karyotype**                                                          ***PAX5*fusion gene**   **Reference**
  --------------------------------------------------------------- --------- --------- --------------- ---------------------------------------------------------------------- ----------------------- ---------------
                                 1                                   37         M          B-III      46,XY,t(7;9)(q11;p13)\[17\]                                            PAX5 ex7/ELN ex2        \[[@B2]\]
                                 2                                   16         M          B-II       46,XY,t(7;9)(q11;p13),del(9)(p21)\[14\]/                               PAX5 ex7/ELN ex2        \[[@B2]\]
                            46,XY\[1\]                                                                                                                                                               
                                 3                                    4         M           B-I       46,XY,t(7;9)(q11;p13)\[2\]/                                            PAX5 ex7/ELN ex2        \[[@B4]\]
                            46,XY\[18\]                                                                                                                                                              
                                 4                                   1.4        M          B-ALL      NA (9906_037)                                                          PAX5 ex5/ELN\*          \[[@B8]\]
                                 5                                  19.4        M          B-III      46,XY,?add(4)(q2?),?add(5)(p14),del(8)(p21),der(9)t(7;9)(q11.2;p13),   PAX5 ex7/ELN ex5        This work
   del(16)(p13),inc\[cp16\]/46,idem,?dup(1)(q21)\[3\]/46,XY\[4\]                                                                                                                                     
                                 6                                   3.1        M          B-III      45,XY,-7,der(9)t(7;9)(q11;p13)\[15\]/                                  PAX5 ex6/AUTS2 ex4      \[[@B5]\]
                            46,XY\[1\]                                                                                                                                                               
                                 7                                   2.8        F          B-III      45,XX,-7,der(9)t(7;9)(q11;p13),dup(16)(p11p13)\[14\]/                  PAX5 ex6/AUTS2 ex6      \[[@B9]\]
                            46,XX\[2\]                                                                                                                                                               
                                 8                                   0.6        M        B-II/III     46,XY,t(7;9)(q11;p13)\[8\]                                             PAX5 ex6/AUTS2 ex5      \[[@B10]\]
                                 9                                   2.1        M          B-III      46,XY,del(7)(q22q33)?,del(9)(q22?),del(12)(p11)\[8\]                   PAX5 ex5/POM121 ex4     \[[@B1]\]
                                10                                    1         M          B-III      46,XY,t(7;9)(q11;p13)\[21\]/                                           PAX5 ex5/POM121 ex4     \[[@B4]\]
                            46,XY\[3\]                                                                                                                                                               
                                11                                   1.7        F          B-ALL      45,XX,-7,der(9)t(7;9)(q11;p13)\[17\]                                   NA                      \[[@B12]\]
                            46,XX\[2\]                                                                                                                                                               
                                12                                   1.3        M          B-ALL      45,XY,inv(1)(p35q32),-7,der(9)t(7;9)(q11;p13)\[31\]                    NA                      \[[@B13]\]
                            46,XY\[17\]                                                                                                                                                              

All cases, except cases 4 and 9, are listed in the Mitelman database from which also the respective karyotypes have been retrieved \[[@B11]\].

\**PAX5* exon 5 is fused to an unknown *ELN* exon.

NA, data not available.

![**Cytogenetic and molecular genetic analysis of a*PAX5-ELN*positive case. (A)** Karyogram; red arrow indicates the derivative chromosome der(9)t(7;9)(q11.23;p13) (refined karyotype using molecular methods). **(B)** FISH using *PAX5*-specific BAC clones showing a 3′-end deletion: 5′-end-specific clone (red signals); 3′-end-specific clone (green signals); black and red arrows indicate the normal and derivative chromosome, respectively. **(C)** FISH using *PAX5-* and *ELN*-specific BAC clones showing a co-localization: *PAX5* 5′-end-specific clone (red signals); *ELN* 3′-end-specific clone (green signals); arrows indicate the normal chromosomes 9 and 12 (white) and the derivative chromosome (black). **(D)** RT-PCR using primers located in *PAX5* exon 2--3 and *ELN* exon 6 resulting in amplification of *PAX5-ELN* fusion transcripts. M, molecular weight marker DNA-mix ladder (Peqlab); lane 1, patient No. 5; lane 2, normal control. **(E)** Sequence chromatogram of the *PAX5-ELN* fusion junction showing the fusion between exon 7 of *PAX5* and exon 5 of *ELN*.](1755-8166-7-13-1){#F1}

![**Schematic representation of the structure of PAX5 and the putative consensus chimeric proteins.** PD, paired domain; 8, octapeptide; HD, partial homeodomain; TA, transactivation domain; I, inhibitory domain; P, proline-rich regions; H, histidine-rich regions; KA, alanine-rich cross-linking domains; KP, proline-rich cross-linking domains; HY, hydrophobic domains; 6, VGVAPG hexapeptide domain; C, C-terminal domain; i, insertion; N, POM121 5′-untranslated region; FG, FG-repeats; arrows and filled lollipops indicate nuclear localization signals and fusion breakpoints, respectively.](1755-8166-7-13-2){#F2}

Results and discussion
======================

So far, sixteen in-frame *PAX5*-fusions have been described and the fusion partners comprise a heterogeneous group of genes encoding proteins, which play distinct roles in signaling, transcription, chromatin remodeling, and cell structuring \[[@B1]-[@B7],[@B9],[@B10]\]. Three of the sixteen currently known *PAX5* fusion partners, namely, *AUTS2*, *ELN*, and *POM121*, are located at the pericentromeric region of 7q and encompass roughly 3.3 Mb of genomic DNA, forming the only currently known cluster of *PAX5* partner genes. Therefore, t(7;9)(q11.2;p13) translocations may give rise to three different recurrent fusion genes, i.e. *PAX5-AUTS2*, *PAX5-POM121*, and *PAX5-ELN* (Figure [2](#F2){ref-type="fig"}), which are not distinguishable at the cytogenetic level. In addition, karyotyping of five of the cases showed an unbalanced der(9)t(7;9)(q11.2;p13) with loss of the reciprocal derivative chromosome (Table [1](#T1){ref-type="table"}; cases 5--7 and 11--12). One of the cases was identified by SNP array (case 4), only detecting unbalanced chromosome alterations; furthermore, most cases showed a deletion of the *PAX5* 3′-end by FISH, further supporting the notion that the *PAX5-*partner fusions, and not the reciprocal ones contribute to leukemogenesis.

t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) positive leukemia is a rare disease and only 9 cases have been collected in the Mitelman database of the cancer genome anatomy project (\[[@B11]\] accessed November 2013) (Table [1](#T1){ref-type="table"}). Three of these cases were *PAX5-ELN* positive \[[@B2],[@B4]\] and in addition, a case with a *PAX5-ELN* fusion without cytogenetic data has been reported \[[@B8]\]. Together, including the case described herein, five patients harboring this fusion gene have now been identified.

Other cases involving the cluster of *PAX5* fusion partners include: Three patients with a *PAX5-AUTS2*\[[@B5],[@B9],[@B10]\], two with a *PAX5-POM121* fusion gene \[[@B1],[@B4]\], and in two cases involvement of *PAX5* has not been investigated \[[@B12],[@B13]\] (Table [1](#T1){ref-type="table"}). Of note, in the *PAX5-POM121* case we have previously published \[[@B1]\], cytogenetic analysis failed to identify a t(7;9)(q11.2;p13), but the chromosome quality was rather poor. Whole chromosome painting with probes specific for chromosomes 7 and 9 showed the presence of a der(7;9), on which the 3′-end of *PAX5* was located, whereas the 5′-end of *PAX5*, generating the *PAX5-POM121* fusion, was translocated to a derivative chromosome, which only partially consisted of chromosome 7 material (data not shown). Together, with the molecular data that showed an insertion of chromosome 12 sequences in the fusion, a more complex rearrangement with involvement of at least chromosomes 7, 9, and 12 generated the in-frame *PAX5-POM121* fusion \[[@B1]\].

Furthermore, out of the 12 cases with t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) rearrangements only one was an adult and two were young adolescents, whereas all other patients were ≤ 4 years of age (Table [1](#T1){ref-type="table"}), suggesting that this subtype of leukemia occurs more frequently in pediatric than in adult cases. Remarkably, 83% (10/12) of the t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) patients were male, and thus, the male/female ratio was 5. Although the number of so far reported cases is rather low, in acute leukemia such an extreme gender bias is exceedingly rare \[[@B14]\]. This finding is intriguing, but currently there is no plausible explanation why a specific subtype of leukemia is associated with one or the other gender.

Regarding the prognostic relevance of *PAX5* fusion genes in general, due to their rareness no final conclusions may be drawn. However, we have recently shown that *PAX5-AUTS2* leukemia may have a rather unfavorable outcome \[[@B10]\]. Out of the five *PAX5-ELN* cases, one patient (case 4) showed high-risk features and displayed a *JAK1* mutation and a *BCR-ABL1*-like expression signature \[[@B8]\]. Furthermore, cases 1 and 2 both relapsed post allograft and died 16 months after initial diagnosis (\[[@B15]\] accessed November 2013). The *PAX5-ELN* positive patient presented herein is currently, eight months after initial diagnosis, in complete remission. Together, there is at least some evidence that t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) leukemia may have a rather poor prognosis. However, whether this is attributable to the specific *PAX5*-fusions or to coinciding mutations in, for example, tyrosine kinases, remains to be determined, and a larger cohort of patients needs to be analyzed, which, due to the low incidence of this leukemia subtype, will require an international collaborative effort.

Conclusion
==========

In this report an additional case of *PAX5-ELN* positive leukemia is described, and, furthermore, an overview of the published cases of t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) leukemia is given, emphasizing the importance of molecular analysis to discriminate between cytogenetically identical translocations resulting in distinct fusion genes.

Material and methods
====================

Cytogenetic and fluorescence in situ hybridization (FISH) analysis
------------------------------------------------------------------

Cytogenetic analysis was performed according to standard techniques. FISH analysis using *PAX5*- and *ELN*-specific probes was conducted as previously described \[[@B1]\]. The *PAX5* rearrangement was first detected using *PAX5*-flanking BAC clones RP11-220I1 and RP11-12P15 (obtained from Pieter de Jong, BACPAC Resources, Children's Hospital and Research Center Oakland, CA, USA). Verification of the *PAX5-ELN* fusion was performed using the *PAX5* 5′-end-flanking BAC clone RP11-220I1 in combination with the *ELN* 3′-end-specific clone RP11-349P21 (Welcome Trust Sanger Institute; <http://www.sanger.ac.uk>).

RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
--------------------------------------------------------------------------

RNA isolation and RT-PCR for the detection of *PAX5*-*ELN* transcripts were performed according to standard procedures using primers PAX5ex2-3-F1 (5′-TCTTGGCAGGTATTAT GAGACAGGAAG-3′) and ELNex6-R2 (5′-AGCAGCGTCAGCCACTCCAC-3′) located in exons 2--3 and 6 of *PAX5* and *ELN*, respectively. Amplification products were directly sequenced (Microsynth AG, Austria) and sequence analysis was conducted using the CLC Main Workbench 6.0 (CLC bio, Denmark).

Reference sequences and exon nomenclature
-----------------------------------------

The chromosome band positions of the genes and the exon nomenclature used correspond to that of the Ensemble database and the reference sequences for *AUTS2* (ENST00000342771), *ELN* (ENST00000252034), *POM121* (ENST00000257622), and *PAX5* (ENST00000358127) (Ensembl release 73 - September 2013). A summary of all mRNA fusion sequences as well as the entire transcript and protein sequences of the putative consensus chimeras PAX5-AUTS2, PAX5-ELN, and PAX5-POM121 are provided as Additional file [1](#S1){ref-type="supplementary-material"}.
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